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Background: Docetaxel is a key antineoplastic drug for treatment of non-small cell lung cancer. Ocular adverse
events of docetaxel include epiphora (excess tearing) and conjunctivitis. Epiphora has been reported to be
associated with canalicular and nasolacrimal duct stenosis, but it is not necessarily caused by lacrimal duct
obstruction.
Case presentation: We encountered three Japanese non-small cell lung cancer patients who developed
epiphora after the administration of docetaxel-based chemotherapy. One patient with lacrimal puncta stenosis
showed improvement with probing and irrigation. The other two patients resolved following cessation of
docetaxel or administration of artificial tears.
Conclusion: As epiphora can interfere with activities of daily life and negatively affect quality of life, it is
important for thoracic oncologists to be aware of this adverse event.
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Docetaxel is a highly effective chemotherapeutic agent
for non-small cell lung cancer (NSCLC) [1]. Common
adverse events are neutropenic fever, anemia, fluid re-
tention, hypersensitivity reactions, anorexia, myalgia,
mucositis, alopecia, skin and nail toxicity, and peripheral
neuropathy [2]. Epiphora (excessive tearing) was re-
ported to occur in up to 64% of breast cancer patients
receiving docetaxel-based chemotherapy [3]. It has been
suggested that tearing may result from canalicular and
nasolacrimal duct stenosis [4]; however, Chan et al. [5]
reported that epiphora was not necessarily caused by
lacrimal duct obstruction in breast cancer patients re-
ceiving adjuvant docetaxel-based combination chemother-
apy. Although docetaxel is a key antineoplastic drug for
NSCLC treatment, there have been few reports regarding
epiphora in patients with NSCLC. Here, we report three
NSCLC patients who developed epiphora after the admin-
istration of docetaxel-based chemotherapy.* Correspondence: ntakigaw@med.kawasaki-m.ac.jp
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Case 1
A 52-year-old Japanese man was referred to our hospital
for treatment of advanced NSCLC. Six years previously,
he had received chest radiotherapy with concurrent
chemotherapy, including cisplatin and docetaxel [6]. He
had received several chemotherapeutic treatments after
progression of the disease. Finally, he was treated with do-
cetaxel monotherapy (60 mg/m2 on day 1 of every 21-day
cycle) as seventh-line chemotherapy. The patient achieved
stable disease. After a cumulative dose of 520 mg/m2, in-
cluding first-line chemotherapy, he developed epiphora of
both eyes, nail changes, and fluid retention as adverse
events. Docetaxel was discontinued, but the epiphora
became progressively worse, leading to a referral for oph-
thalmic opinion and management. On ophthalmological
examination, mild stenosis of the lower lacrimal puncta
was revealed by slit-lamp microscopy (Figure 1A). The
epiphora improved immediately by probing and irrigation
of the eye (Figure 1B).
Case 2
A 68-year-old Japanese woman was treated with doce-
taxel monotherapy (60 mg/m2 on day 1 of every 21-day
cycle) as third-line chemotherapy. The patient achievedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Slit-lamp examination of the left eye and irrigation of the nasolacrimal duct. Slit-lamp examination of the left eye revealed
stenosis of the lower lacrimal puncta, which the arrow pointed to (A). Probing and irrigation of the nasolacrimal duct was performed (B).
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she developed epiphora of both eyes and nail changes.
The results of an ophthalmological examination were
almost normal except for detection of cataracts. There
was no evidence of lacrimal duct obstruction. Treatment
with docetaxel was discontinued because of the adverse
events. Although excessive tearing improved gradually
over 2 months, the epiphora had not resolved com-
pletely at 5 months after cessation of docetaxel.
Case 3
A 67-year-old Japanese woman was treated with docetaxel
(60 mg/m2 on day 1 of every 21-day cycle) and bevacizu-
mab (15 mg/kg on day 1 of every 21-day cycle) as tenth-
line chemotherapy. Six years previously, she had received
chemotherapy with carboplatin and docetaxel. She com-
plained of epiphora and discomfort of both eyes after a
cumulative dose of 720 mg/m2 of docetaxel, including
first-line chemotherapy. An ophthalmological examination
revealed only dry eye, and no lacrimal duct obstruction
was observed. Her ocular symptoms slowly improved with
the administration of artificial tears and sodium hyalur-
onate. The chemotherapy was continued for disease
stabilization.
Discussion
We experienced three patients with advanced NSCLC
who developed epiphora after the administration of
docetaxel-based chemotherapy. Common ocular toxic-
ities associated with docetaxel administration include
epiphora and conjunctivitis [7]. Chan et al. [5] reported
that the incidences of tearing and other eye symptoms
associated with docetaxel-based treatment was 86%, sug-
gesting that epiphora was one of the most common ad-
verse events. Excessive tearing interferes with daily life
activities such as driving, reading, and visual tasks. The
frequency and severity of epiphora increased with weekly
administration of docetaxel compared with adminis-
tration every 3 weeks [8]. In addition, ocular toxicityoccurred in patients receiving a median or mean cumula-
tive docetaxel dose of 300 or 400 mg/m2 or a higher dose
[9]. Cumulative doses of docetaxel in our cases were all
more than 500 mg/m2. The relations of the patients’ doce-
taxel exposures to expected incidence rates were prospect-
ively analyzed [5]. There was a trend for lower rates of
tearing in patients receiving lower cumulative doses of do-
cetaxel. However, we should be aware that the combined
drug with docetaxel such as fluorouracil can affect the
rates.
Canalicular stenosis associated with docetaxel is most
likely caused by secretion of docetaxel in the tear film
and resultant chronic inflammation of the canaliculi due
to direct contact with the drug as the tears travel
through the canaliculi and the nasolacrimal duct to
drain into the nose [4,9,10]. Importantly, epiphora oc-
curs either with or without the presence of lacrimal duct
obstruction [5], the latter being considered reactive tear-
ing to ocular dryness [11]. Mild to moderate epiphora
may resolve without medical or surgical intervention
after discontinuation of docetaxel [4]. However, delayed
recognition and management of this adverse event can
lead to severe lacrimal duct obstruction that cannot be
managed with silicon intubation and requires more
complicated surgery [4]. The use of eye drops such as
artificial tears may wash out docetaxel from the ocular
surface and thereby prevent the development of dacryos-
tenosis [11].
Epiphora associated with the treatment using other
taxane, paclitaxel, seems to be rare. A patient who was
treated with paclitaxel for angiosarcoma of the head and
neck developed epiphora [12]. A phase III study compar-
ing the efficacy of docetaxel and paclitaxel, given either
weekly or every 3 weeks, in the adjuvant treatment of
breast cancer showed that grade 3 and 4 tearing was re-
ported in 5% of patients who received weekly docetaxel
versus less than 1% of patients who received docetaxel
once every 3 weeks, weekly paclitaxel, or paclitaxel once
every 3 weeks [13]. The study also revealed that grade 2
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addition, ocular toxicities in NSCLC treated with pacli-
taxel did not include epiphora [7]. In terms of similar ef-
fectiveness of the two taxanes for NSCLC, a patient
receiving docetaxel with toxicity of epiphora may change
the chemotherapeutic drug to paclitaxel.
Excessive tearing in our three cases improved gradually
with timely diagnosis and management. One patient with
mild punctal stenosis was improved by probing and irri-
gation. In the other two patients, epiphora was resolved
by discontinuation of docetaxel or use of artificial tears.
When the symptoms do not resolve, epiphora has a sub-
stantial negative impact on the patient’s quality of life. Our
experience with patients who have developed epiphora
suggests that ophthalmological examination and careful
monitoring during docetaxel treatment may lead to suc-
cessful management and reduced ocular toxicity.
Conclusion
In conclusion, it is important for oncologists to be aware
of this adverse event, and ophthalmologists should be
consulted in cases in which tears appear during doce-
taxel therapy.
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